Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
The Journal of Infectious Diseases|December 12, 2013
Toll-like receptor polymorphism associations with HIV-1 outcomes among sub-Saharan AfricansRomel D Mackelprang, Abigail W Bigham, Connie Celum, et al.
Cell Reports. Medicine|July 1, 2021
CD101 genetic variants modify regulatory and conventional T cell phenotypes and functionsLaura E Richert-Spuhler, Corinne M Mar, Paurvi Shinde, et al.
Vaccine|March 26, 2016
Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trialGuy de Bruyn, Jamshid Saleh, David Workman, et al.
Vaccine|October 11, 2005
A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjectsGuy de Bruyn, Mauricio Vargas-Cortez, Terri Warren, et al.
Plos One|January 10, 2008
Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trialJairam R Lingappa, Barrot Lambdin, Elizabeth Ann Bukusi, et al.
Plos One|December 17, 2011
Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposureJairam R Lingappa, Slavé Petrovski, Erin Kahle, et al.
Vaccine|June 7, 2015
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trialHennie Geldenhuys, Helen Mearns, David J C Miles, et al.
The Lancet. Infectious Diseases|May 17, 2011
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b studyGlenda E Gray, Mary Allen, Zoe Moodie, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging studyPaul A Goepfert, Bo Fu, Anne-Laure Chabanon, et al.
The Lancet. Infectious Diseases|September 18, 2020
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trialGuy de Bruyn, David L Gordon, Theodore Steiner, et al.
Pageof 9